Biogen (NASDAQ: RUBY) and Rubius Therapeutics (NASDAQ:RUBY) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, institutional ownership, analyst recommendations and risk.

Analyst Ratings

This is a summary of current recommendations and price targets for Biogen and Rubius Therapeutics, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biogen 0 9 20 0 2.69
Rubius Therapeutics 0 0 4 0 3.00

Biogen currently has a consensus target price of $375.52, suggesting a potential upside of 10.88%. Rubius Therapeutics has a consensus target price of $38.50, suggesting a potential upside of 73.50%. Given Rubius Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Rubius Therapeutics is more favorable than Biogen.

Insider & Institutional Ownership

87.5% of Biogen shares are owned by institutional investors. 0.3% of Biogen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Biogen and Rubius Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Biogen 23.06% 38.17% 20.41%
Rubius Therapeutics N/A N/A N/A

Earnings & Valuation

This table compares Biogen and Rubius Therapeutics’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Biogen $12.27 billion 5.56 $2.54 billion $21.81 15.53
Rubius Therapeutics N/A N/A N/A N/A N/A

Biogen has higher revenue and earnings than Rubius Therapeutics.

Summary

Biogen beats Rubius Therapeutics on 7 of the 9 factors compared between the two stocks.

About Biogen

Biogen Inc. discovers, develops, manufactures, and delivers therapies for the treatment of neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis (MS); FUMADERM for the treatment of plaque psoriasis; and SPINRAZA to treat spinal muscular atrophy. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), and other conditions; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of primary progressive MS and relapsing MS, and other anti-CD20 therapies. In addition, the company is developing BAN2401, which has completed Phase II clinical trial for the treatment of Alzheimer's disease, as well as Elenbecestat that is in Phase III clinical trial for treatment of early Alzheimer's disease. The company's Phase II clinical trial products comprise Opicinumab for MS; BIIB092 for PSP; Natalizumab for Acute Ischemic Stroke and Epilepsy; and BG00011 for idiopathic pulmonary fibrosis. Its Phase I/IIa clinical trial products consist of BIIB080 for patients with mild Alzheimer's disease. The company's Phase I clinical trial products comprise Aducanumab for Alzheimer's disease; BIIB076, an anti-tau monoclonal antibody; and BIIB054 for Parkinson's disease. Biogen Inc. offers products through its sales force and marketing groups. It has strategic collaboration with Ionis Pharmaceuticals to develop drug candidates for neurological diseases. The company was formerly known as Biogen Idec Inc. and changed its name to Biogen Inc. in March 2015. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.

About Rubius Therapeutics

Rubius Therapeutics, Inc. focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases through its rubius erythrocyte design cellular therapy platform. The company is developing various RCTs, such as RTX-134 for treatment of classic and moderate phenylketonuria; RTX-Uricase/URAT1 for treatment of chronic refractory gout; RTX-CBS for treatment of homocystinuria; RTX-OxOx for the treatment of second-line hyperoxaluria; and RTX-ALAD for the treatment of acute intermittent porphyria. It is also developing RTX-212 and RTX-4-1BBL for treatment of solid tumors; RTX-212 for hematological cancer; RTX-aAPC to treat solid and hematological cancers; and other product candidates for autoimmune disorders. The company was founded in 2013 and is based in Cambridge, Massachusetts.

Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.